Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ICUI · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortICU MEDICAL INC/DE is profitable, generates cash and carries moderate debt, with revenue shrinking (−6.3% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.9% | 23/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 0.0% | 20/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 0.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 1.0% | 7/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.39× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.60× | 78/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 4.01× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.46× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.90 | 46/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 4.1% | 36/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 125.42× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 32.9% | 0/100 |
| Operating margin volatility | 4.2% | 71/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -0.7% | 13/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,316 | 2,280 | 2,259 | 2,382 | 2,231 |
| Cost of revenue | 825 | 1,582 | 1,519 | 1,557 | 1,409 |
| Gross profit | 491 | 698 | 740 | 825 | 822 |
| Research & development | 47 | 93 | 85 | 89 | 87 |
| Selling, general & admin | 303 | 608 | 607 | 639 | 625 |
| Operating income | 123 | (43) | 23 | 43 | 43 |
| Interest expense | 0.9 | 71 | 103 | 107 | 93 |
| Pre-tax income | 81 | (136) | (78) | (66) | 4.4 |
| Income tax | 20 | (40) | (49) | 52 | 2.4 |
| Net income | 103 | (74) | (30) | (118) | 0.7 |
| Diluted EPS | $4.74 | −$3.11 | −$1.23 | −$4.83 | $0.03 |
| Diluted shares (millions) | 22 | 24 | 24 | 24 | 25 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
2.90 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026